Skip to main content

Drug Interactions between trientine and VP-GSTN

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

trientine zinc glycinate

Applies to: trientine and VP-GSTN (cholecalciferol / genistein / zinc glycinate)

When used concomitantly with copper-chelating agents for the treatment of Wilson's disease, zinc salts can compete with copper for chelation and renal excretion. The clinical significance is unknown, although reduced efficacy of one or both agents may theoretically occur. Zinc alone can reduce copper levels by blocking its absorption in the intestine and promoting fecal copper excretion. A small study found that adding penicillamine (1 gm/day) or trientine (1 gm/day) to zinc therapy reduced fecal copper excretion but increased urinary excretion, with the overall copper balance not appreciably changed compared to during zinc therapy alone. In the study, the chelating agent and zinc were given one hour apart. It is not known if simultaneous administration would result in more clinically significant alterations. Other studies have reported on the effectiveness of combination therapy in some patients. However, no data are available to demonstrate that zinc should be added to other drugs used for the treatment of Wilson's disease.

References

  1. Farinati F, Cardin R, Mestriner C, Sturniolo GC, Naccarato R "Mechanisms of pennicillamine and zinc in the treatment of Wilson's disease." Am J Gastroenterol 90 (1995): 2264-5
  2. Brewer GJ "Practical recommendations and new therapies for Wilson's disease." Drugs 50 (1995): 240-9
  3. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y "Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents." J Am Coll Nutr 12 (1993): 26-30
  4. "Product Information. Galzin (zinc acetate)." Teva Pharmaceuticals USA PROD (2001):
  5. Anderson LA. Hakojarvi SL, Boudreaux SK "Zinc acetate treatment in Wilson's disease." Ann Pharmacother 32 (1998): 78-87
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Moderate

trientine food

Applies to: trientine

ADJUST DOSING INTERVAL: The gastrointestinal absorption of trientine may be decreased in the presence of food, resulting in reduced therapeutic effects.

MANAGEMENT: Trientine should be administered on an empty stomach, at least one hour before or two hours after meals and at least one hour apart from any other food, drug, or milk.

References

  1. "Product Information. Syprine (trientine)." Aton Pharma PROD (2001):

Switch to consumer interaction data

Moderate

trientine food

Applies to: trientine

GENERALLY AVOID: Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.

MANAGEMENT: In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine. If concomitant use is unavoidable, separation of administration times by at least two hours is advisable.

References

  1. "Product Information. Syprine (trientine)." Aton Pharma PROD (2001):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. Cerner Multum, Inc. "Australian Product Information." O 0

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer